These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36907547)

  • 1. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
    Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
    Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
    de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
    J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
    Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
    J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
    Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
    Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
    Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
    Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
    J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
    PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
    Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
    J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.
    Bodansky A; Vazquez SE; Chou J; Novak T; Al-Musa A; Young C; Newhams M; Kucukak S; Zambrano LD; Mitchell A; Wang CY; Moffitt K; Halasa NB; Loftis LL; Schwartz SP; Walker TC; Mack EH; Fitzgerald JC; Gertz SJ; Rowan CM; Irby K; Sanders RC; Kong M; Schuster JE; Staat MA; Zinter MS; Cvijanovich NZ; Tarquinio KM; Coates BM; Flori HR; Dahmer MK; Crandall H; Cullimore ML; Levy ER; Chatani B; Nofziger R; ; Geha RS; DeRisi J; Campbell AP; Anderson M; Randolph AG
    J Allergy Clin Immunol; 2023 Apr; 151(4):926-930.e2. PubMed ID: 36509151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of autoantibodies to type I interferon in patients suffering from long COVID.
    Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH
    J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
    Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
    J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis.
    da Silva RP; Gonçalves JIB; Zanin RF; Schuch FB; de Souza APD
    Front Immunol; 2021; 12():657363. PubMed ID: 34054820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
    Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
    J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
    Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
    Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
    Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
    J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
    Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Ohara O; Tanaka J; Morio T; Okada S
    J Clin Immunol; 2022 Oct; 42(7):1360-1370. PubMed ID: 35764767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.
    Jiang W; Johnson D; Adekunle R; Heather H; Xu W; Cong X; Wu X; Fan H; Andersson LM; Robertson J; Gisslén M
    J Med Virol; 2023 Jan; 95(1):e28134. PubMed ID: 36086941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Presence of Antibodies against Type I Interferons and Human Endogenous Retrovirus W in Intensive Care Unit COVID-19 Patients.
    Simula ER; Manca MA; Noli M; Jasemi S; Ruberto S; Uzzau S; Rubino S; Manca P; Sechi LA
    Microbiol Spectr; 2022 Aug; 10(4):e0128022. PubMed ID: 35852349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
    Meager A; Visvalingam K; Peterson P; Möll K; Murumägi A; Krohn K; Eskelin P; Perheentupa J; Husebye E; Kadota Y; Willcox N
    PLoS Med; 2006 Jul; 3(7):e289. PubMed ID: 16784312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.